title: Thromboxane A2 interferes with a disposal process of aggregated protein in glomeruli.
abstract: Immune complexes in glomeruli are involved in development of diverse glomerulonephritis. The disposal process of glomerular immune complexes has been unclarified. The present studies were undertaken to determine if thromboxane A2 (TXA2) is associated with the disposal of macromolecules in the glomeruli using mice injected with aggregated bovine serum albumin (a-BSA). A-BSA promptly accumulated in the glomeruli, the level reaching a plateau at 6 hr after the injection of a-BSA, and then decreased by 48 hr. The production of glomerular TXA2, prostaglandin E2 (PGE2) and prostaglandin I2 concomitantly increased with the decrease of a-BSA in the glomeruli. TXA2 synthase inhibitors and TXA2 receptor antagonists accelerated clearance of glomerular a-BSA without enhancing renal tissue blood flow. They did not affect a-BSA level in the plasma. In contrast, aminophylline, dopamine and mannitol significantly increased renal tissue blood flow, but did not decrease glomerular a-BSA. TXA2 synthase inhibitors decreased TXA2 production in the glomeruli. TXA2 synthase inhibitors and TXA2 receptor antagonists did not influence the generation of PGE2. The TXA2 analogue U-46619 significantly increased the accumulation of a-BSA in the glomeruli. We propose that TXA2 interferes with the disposal process of aggregated protein in the glomeruli. We also postulate that interception of glomerular activity of TXA2 may be an effective intervention for managing immune complex-mediated glomerulonephritis and glomerulosclerosis.
authors.affiliation: Department of Pharmacology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nagamatsu
authors.forename: T
authors.initials: T
authors.lastname: Nagao
authors.forename: Y
authors.initials: Y
authors.lastname: Nomura
authors.forename: Y
authors.initials: Y
authors.lastname: Suzuki
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000818:Animals; D015232:Dinoprostone / Q000378:metabolism; D011464:Epoprostenol / Q000378:metabolism; D005921:Glomerulonephritis / Q000276:immunology / Q000378:metabolism; D005923:Glomerulosclerosis, Focal Segmental / Q000276:immunology / Q000378:metabolism; D007678:Kidney Glomerulus / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors; D012079:Renal Circulation / Q000187:drug effects; D012710:Serum Albumin, Bovine / Q000378:metabolism* / Q000493:pharmacokinetics; D013928:Thromboxane A2 / Q000031:analogs & derivatives / Q000378:metabolism*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D017482:Receptors, Thromboxane; D014662:Vasoconstrictor Agents; D012710:Serum Albumin, Bovine; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D011464:Epoprostenol; D013930:Thromboxane-A Synthase; D015232:Dinoprostone